What happened with MPLT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
MapLight Therapeutics is a clinical-stage biotechnology company whose lead drug candidate, ML-007C-MA, is being tested for schizophrenia and psychosis associated with Alzheimer’s disease. It combines two compounds in a fixed dose and is in the Phase 2 ZEPHYR and VISTA trials for those respective conditions. MapLight also develops ML-004 for symptoms of autism spectrum disorder.
The company has no approved products and has generated no revenue. Share sales and research grants have funded its work, and it needs further financing to complete development. Its intended product-sales business depends first on successful clinical trials and regulatory approval; U.S. sales would then depend partly on government and private insurers covering and reimbursing treatment. MapLight relies on outside manufacturers for drug supplies, including a limited number of single-source suppliers for components of ML-007C-MA, and plans to build U.S. sales and distribution capabilities if a drug is approved.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Bristol Myers Squibb competes with both initial uses of MapLight’s ML-007C-MA: it sells Cobenfy for schizophrenia and is developing it for Alzheimer’s disease psychosis. Watch Cobenfy’s progress in Alzheimer’s psychosis, where MapLight says no medicine has FDA approval for that use.
Neurocrine Biosciences is developing several schizophrenia drugs that act on muscarinic receptors and could compete directly with MapLight’s ML-007C-MA. Progress on direclidine, NBI-'570 and NBI-'567 is the relevant signal for MapLight, rather than Neurocrine’s existing INGREZZA sales.
Neumora Therapeutics and MapLight are developing schizophrenia drugs that act on muscarinic receptors, so their clinical results speak to the same treatment opportunity. Neumora’s work is at an earlier stage; it had no approved or commercialized products and no product-sales revenue through December 31, 2025.
Acadia Pharmaceuticals’ ACP-204 targets Alzheimer’s disease psychosis, competing for the same patients as MapLight’s ML-007C-MA but acting through other receptors. Watch ACP-204’s development rather than equating it with Acadia’s marketed NUPLAZID, which treats hallucinations and delusions associated with Parkinson’s disease psychosis.
LB Pharmaceuticals’ oral schizophrenia candidate LB-102 is in Phase 3, ahead of MapLight’s Phase 2 ML-007C-MA in development for the same treatment market. Its schizophrenia trial results are the news to watch for MapLight, distinct from LB-102’s development for other psychiatric disorders.
AbbVie’s emraclidine could compete with MapLight’s ML-007C-MA: both are being developed for schizophrenia and act on muscarinic receptors. Emraclidine’s clinical performance is the part of this broad medicine developer’s news that informs MapLight’s competitive opportunity.
Alto Neuroscience’s schizophrenia program competes for a treatment market also targeted by MapLight’s ML-007C-MA. Focus on results in schizophrenia patients: Alto’s clinical pipeline also covers depression and Parkinson’s disease, so not every trial update bears on MapLight.
Minerva Neurosciences develops roluperidone for the same schizophrenia patient population as MapLight, but targets negative symptoms, a distinct treatment need. Read roluperidone’s results in that narrower context rather than as a direct comparison with MapLight’s ML-007C-MA.
Fed Interest Rate Decision
MapLight earns interest on its cash, cash equivalents and investments, so Fed rate decisions can change what it earns on those funds.
Expected4.0%Last release4.0%
If it comes in above expectations
If the policy rate is higher than expected, MapLight may earn more interest on its funds as rates rise, increasing its other income.
If it comes in below expectations
If the policy rate is lower than expected, MapLight may earn less interest on its funds as rates fall, reducing its other income.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb’s report can show whether its development of Cobenfy for Alzheimer’s disease psychosis is advancing, a patient group MapLight is also targeting.
Focus on updates about Cobenfy’s development for Alzheimer’s disease psychosis, not its separate marketed use for schizophrenia. If development advances, another company is moving toward a patient group MapLight also targets, creating potential future competition. If it encounters setbacks, that opportunity may be less crowded for now, but this does not establish that MapLight’s candidate works.
MapLight Therapeutics, Inc. earningsThis company
MapLight Therapeutics has no product-sales revenue, so this report will show whether clinical-development spending and cash use still fit the time its available resources are expected to support operations.
Read R&D expense, cash used in operating activities and cash and investments at period-end together. R&D expense shows the development costs recorded in the accounts; operating cash use shows how much cash operations consumed. If cash use speeds up relative to resources on hand, MapLight may need to seek funding sooner or slow its programs. If cash use stays controlled and resources remain consistent with the company’s stated expectation of funding operations through 2027, its existing funds are more likely to support continued clinical development.
